Elranatamab versus physician’s choice of treatment in patients with triple-class exposed/refractory multiple myeloma: an updated matching-adjusted indirect comparison
Aim: Despite the availability of novel treatment options for patients with triple-class exposed/refractory multiplemyeloma , there is a lack of consensus on the optimal regimen. A previous unanchored matchingadjusted indirect comparison (MAIC) of the MagnetisMM-3 (NCT04649359) and LocoMMotion (NCT...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Becaris Publishing Limited
2025-04-01
|
| Series: | Journal of Comparative Effectiveness Research |
| Subjects: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Aim: Despite the availability of novel treatment options for patients with triple-class exposed/refractory
multiplemyeloma , there is a lack of consensus on the optimal regimen. A previous unanchored matchingadjusted
indirect comparison (MAIC) of the MagnetisMM-3 (NCT04649359) and LocoMMotion (NCT040
35226) study reported significant improvements in progression-free survival (PFS) and overall survival
(OS) with elranatamab versus physician’s choice of treatment. Materials & methods: We conducted an
updated MAIC based on more recent data (28.4 months for MagnetisMM-3). Following reweighting
of MagnetisMM-3 individual patient data to match the LocoMMotion population, the effective sample
size was 64 for PFS and 63 for OS in the base-case analysis. Results: Consistent with the original MAIC,
significantly improved PFS (hazard ratio [HR] [95% confidence interval (CI)]: 0.32 [0.21, 0.50], p < 0.01) and
OS (HR [95% CI]: 0.50 [0.33, 0.78], p < 0.01) were observed with elranatamab versus physician’s choice of
treatment. The robustness of the results was demonstrated in sensitivity analyses in whichmissing baseline
characteristics data for elranatamab were imputed. Conclusion: Overall, the findings of this study align
with and add confidence to the conclusions of the previous MAIC that elranatamab is associated with
significantly improved outcomes versus standard treatment, supporting the value to elranatamab for the
treatment of patients with triple-class exposed/refractory multiple myeloma. |
|---|---|
| ISSN: | 2042-6313 |